Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma

被引：0

作者：

Trneny, Marek

Lamy, Thierry

Walewski, Jan Andrzej

Belada, David

Mayer, Jiri

Radford, John A.

Jurczak, Wojciech

Morschhauser, Franck

Alexeeva, Julia

Rule, Simon

Biyukov, Tsvetan Nikolov

Patturajan, Meera

Bravo, Marie-Laure Casadebaig

Cabecadas, Jose

Arcaini, Luca

机构：

[1] Charles Univ Hosp, Dept Hematol, Prague, Czech Republic

[2] Hop Pontchaillou, Dept Hematol, Rennes, France

[3] Maria Sklodowska Curie Mem Inst & Oncol Ctr, Dept Lymphoid Malignancies, Warsaw, Poland

[4] Charles Univ Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[5] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[6] Univ Manchester, Manchester, Lancs, England

[7] Christie NHS Fdn Trust, Manchester, Lancs, England

[8] Jagiellonian Univ, Dept Hematol, Krakow, Poland

[9] Ctr Hosp Univ Reg Lille, Lille, France

[10] Fed Med Res Ctr, St Petersburg, Russia

[11] Derriford Hosp, Dept Hematol, Plymouth PL6 8DH, Devon, England

[12] Celgene Sarl, Boudry, Switzerland

[13] Celgene Corp, Summit, NJ USA

[14] Inst Portugues Oncol Francisco Gentil, Serv Anat Patol, Lisbon, Portugal

[15] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy

[16] Univ Pavia, Dept Mol Med, I-27100 Pavia, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8547

引用

页数：1

共 50 条

[31] Efficacy and safety of conventional-dose lenalidomide followed by low-dose maintenance lenalidomide for relapsed/refractory mantle cell lymphoma (MCL): updated results from a UK phase II study
Eve, H. E.
Carey, S.
Richardson, S. J.
Heise, C. C.
Mamidipudi, V.
Shi, T.
Radford, J. A.
Auer, R. L.
Bullard, S. H.
Rule, S. A. J.
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 14 - 14
[32] Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
O'Connor, Owen A.
Ozcan, Muhit
Jacobsen, Eric D.
Roncero, Josep M.
Trotman, Judith
Demeter, Judit
Masszi, Tamas
Pereira, Juliana
Ramchandren, Radhakrishnan
Beaven, Anne
Caballero, Dolores
Horwitz, Steven M.
Lennard, Anne
Turgut, Mehmet
Hamerschlak, Nelson
d'Amore, Francesco A.
Foss, Francine
Kim, Won-Seog
Leonard, John P.
Zinzani, Pier Luigi
Chiattone, Carlos S.
Hsi, Eric D.
Truemper, Lorenz
Liu, Hua
Sheldon-Waniga, Emily
Ullmann, Claudio Dansky
Venkatakrishnan, Karthik
Leonard, E. Jane
Shustov, Andrei R.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08) : 613 - +
[33] Phase I/II study of a hybrid schedule of flavopiridol in relapsed/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL)
Tay, K.
Shapiro, G.
Disinski, M.
Chirieac, L. R.
Pittaluga, S.
Jaffe, E. S.
Janik, J. E.
Wiestner, A.
Wilson, W. H.
Dunleavy, K.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[34] Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
S Ferrero
A Pastore
C W Scholz
R Forstpointner
A Pezzutto
L Bergmann
L Trümper
J Finke
U Keller
P Ghione
R Passera
W Hiddemann
O Weigert
M Unterhalt
M Dreyling
Leukemia, 2016, 30 : 984 - 987
[35] Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Romaguera, Jorge E.
Fanale, Michelle A.
Samaniego, Felipe
Fayad, Luis E.
Hagemeister, Fredrick B.
McLaughlin, Peter
Rodriguez, Maria Alma
Weaver, Pam
Hartig, Kim
Badillo, Maria
Kwak, Larry W.
Younes, Anas
Pro, Barbara
Wang, Michael
BLOOD, 2013, 122 (21)
[36] Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
Ferrero, S.
Pastore, A.
Scholz, C. W.
Forstpointner, R.
Pezzutto, A.
Bergmann, L.
Truemper, L.
Finke, J.
Keller, U.
Ghione, P.
Passera, R.
Hiddemann, W.
Weigert, O.
Unterhalt, M.
Dreyling, M.
LEUKEMIA, 2016, 30 (04) : 984 - 987
[37] MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
Andorsky, David J.
Yacoub, Abdulraheem
Bitran, Jacob D.
Melear, Jason
Brooks, Heather D.
Foon, Kenneth A.
Rizvi, Syed
Llorente, Mary
Li, Jiahui
Sharman, Jeff P.
BLOOD, 2016, 128 (22)
[38] Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi
Cavallo, Federica
Clerico, Michele
Lucchini, Elisa
Castiglione, Anna
Re, Alessandro
Zilioli, Vittorio Ruggiero
Visco, Carlo
Tani, Monica
Olivieri, Jacopo
Arcaini, Luca
Fabbri, Alberto
Gaidano, Gianluca
Dodero, Anna
Zaja, Francesco
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (04) : 1404 - 1410
[39] Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 "EMERGE" Study
Goy, Andre
Sinha, Rajni
Williams, Michael E.
Besisik, Sevgi Kalayoglu
Drach, Johannes
Ramchandren, Radhakrishnan
Robertson, Michael J.
Avivi, Irit
Rowe, Jacob M.
Herbrecht, Raoul
Van Hoof, Achiel
Egyed, Miklos
Zhang, Lei
Cicero, Sherri
Fu, Tommy
Witzig, Thomas E.
BLOOD, 2012, 120 (21)
[40] Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
Jerkeman, Mats
Hutchings, Martin
Raty, Riikka
Wader, Karin Fahl
Laurell, Anna
Christensen, Jacob H.
Kuitunen, Hanne
Eskelund, Christian Winther
Groenbaek, Kirsten
Niemann, Carsten Utoft
Geisler, Christian H.
Kolstad, Arne
BLOOD, 2020, 136

← 1 2 3 4 5 →